We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Our proprietary chRDNA (CRISPR hybrid RNA-DNA) technology enables improved genome-editing specificity at high efficiency, and we are applying chRDNA to develop sophisticated genome-edited cell therapies.
Building upon the early successes of autologous cell therapies, we are developing next-generation allogeneic CAR-T and CAR-NK cell therapies with significant potential to address the limitations of patient-derived treatments.
We believe persistence is the key to developing successful allogeneic cell therapies. We use our proprietary technologies to enhance persistence by preventing rejection or rapid exhaustion of donor-derived cell therapies.
“Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technology to develop allogeneic cell therapies that are potentially transformative for patients.”
Jennifer Doudna, Ph.D.
Co-founder of Caribou
Co-recipient of the 2020 Nobel Prize in Chemistry
Join the Herd
Caribou Biosciences is a pioneer at the cutting edge of genome editing and cell therapy development, and we are seeking talented and passionate individuals to join our team.